PBM
SABS icon

Propel Bio Management’s SAB Biotherapeutics SABS Stock Holding History

Propel Bio Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.89M Buy
1,012,790
+359,909
+55% +$1.44M 2.45% 14
2025
Q4 		$2.44M Buy
+652,881
New +$2.15M 2.08% 14

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Propel Bio Management's SABS Position: Q1 2026 in Review

Propel Bio Management increased its SAB Biotherapeutics (SABS) stake by 55% in Q1 2026, buying an estimated $1.44M and bringing the position to 1,012,790 shares worth $3.89M. The position accounts for 2.45% of the portfolio, ranked #14.

Propel Bio Management first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Propel Bio Management held 1,012,790 shares of SAB Biotherapeutics worth $3.89M as of Q1 2026.
  • Propel Bio Management bought 359,909 SAB Biotherapeutics shares in Q1 2026, an estimated $1.44M.
  • SAB Biotherapeutics made up 2.45% of Propel Bio Management's portfolio in Q1 2026, its #14 holding.
  • Propel Bio Management first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.